Aprogen Biologics Inc. (KRX:003060)

Aprogen Biologics Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	12,306	10,053	23,609	35,074	64,796
Short-Term Investments	-	-	390	75,000	140,000
Trading Asset Securities	26,013	-	75,075	14,861	279.12
Cash & Short-Term Investments	38,319	10,053	99,074	124,935	205,075
Cash Growth	281.15%	-89.85%	-20.70%	-39.08%	121.68%
Accounts Receivable	16,607	14,807	17,769	12,825	12,620
Other Receivables	1,682	1,828	4,256	8,259	5,185
Receivables	22,972	23,373	82,060	215,755	119,490
Inventory	52,286	48,128	52,313	10,420	10,040
Prepaid Expenses	895.05	2,490	558.14	10.67	14
Other Current Assets	729.2	812.78	6,604	2,354	1,904
Total Current Assets	115,200	84,857	240,608	353,474	336,523
Property, Plant & Equipment	321,458	318,212	323,773	18,857	19,801
Long-Term Investments	91,994	137,647	57,793	84,232	104,099
Other Intangible Assets	5,116	6,241	6,458	2,796	3,157
Long-Term Accounts Receivable	-	-	-	20,577	-
Long-Term Deferred Tax Assets	-	-	662.84	755.7	658.89
Long-Term Deferred Charges	-	-	-	-	478
Other Long-Term Assets	3,676	3,793	10,099	9,229	31,082
Total Assets	590,984	589,397	684,140	614,621	615,309
Accounts Payable	1,996	1,333	3,809	652.59	808.22
Accrued Expenses	3,756	3,747	4,968	1,201	720.94
Short-Term Debt	103,630	129,360	134,263	2,162	2,621
Current Portion of Leases	2,191	1,360	345.5	199.49	185.77
Current Income Taxes Payable	-	-	4.18	273.93	461.17
Current Unearned Revenue	-	-	-	119.99	119.99
Other Current Liabilities	35,936	22,138	17,716	4,840	3,758
Total Current Liabilities	147,509	157,938	161,106	9,449	8,675
Long-Term Debt	32,000	32,000	-	-	-
Long-Term Leases	16,197	18,277	129.06	120	163.92
Long-Term Deferred Tax Liabilities	3,874	2,932	3,108	1,093	927.58
Other Long-Term Liabilities	2,470	1,827	1,823	1,178	998.31
Total Liabilities	212,294	220,705	173,730	17,440	16,953
Common Stock	99,204	332,877	292,877	199,288	199,288
Additional Paid-In Capital	704,331	358,030	335,850	327,715	327,715
Retained Earnings	-239,199	-133,310	-8,085	-21,115	-30,114
Treasury Stock	-4,485	-4,463	-41.27	-41.27	-41.27
Comprehensive Income & Other	-181,360	-184,443	-194,079	2,092	8,547
Total Common Equity	378,491	368,691	426,521	507,939	505,395
Minority Interest	199.28	-	83,890	89,242	92,961
Shareholders' Equity	378,691	368,691	510,411	597,181	598,356
Total Liabilities & Equity	590,984	589,397	684,140	614,621	615,309
Total Debt	154,017	180,997	134,738	2,481	2,971
Net Cash (Debt)	-115,698	-170,944	-35,664	122,454	202,104
Net Cash Growth	-	-	-	-39.41%	127.99%
Net Cash Per Share	-920.26	-2710.08	-882.32	3072.33	6364.69
Filing Date Shares Outstanding	197.83	65.75	58.57	39.86	39.86
Total Common Shares Outstanding	197.83	65.75	58.57	39.86	39.86
Working Capital	-32,308	-73,081	79,502	344,025	327,848
Book Value Per Share	1913.19	5607.21	7281.63	12744.01	12680.19
Tangible Book Value	373,376	362,451	420,063	505,142	502,238
Tangible Book Value Per Share	1887.33	5512.30	7171.38	12673.85	12600.98
Land	29,664	25,156	28,315	9,313	8,463
Buildings	97,599	97,507	101,378	9,647	10,460
Machinery	179,320	118,620	145,738	10,258	9,494
Construction In Progress	64,463	108,996	90,433	-	392

Updated Mar 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.